News

Moderna’s first quarter was marked by a sharp increase in revenue, driven by the fulfillment of large international contracts, particularly through a strategic partnership in the United Kingdom. Management attributed the strong year-over-year growth to international demand for its COVID vaccine products, with CEO Stéphane Bancel noting, “We grew year-over-year revenues significantly to $0.4 billion, driven primarily by execution of our long-term strategic partnership in the U.K.” Despite these g

On May 11, 2026, AI and chip stocks fueled fresh records as surging oil and valuation warnings tested nerves.

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.19%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.19%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.29%. June E-mini S&P futures (ESM26 ) rose +0.18%, and June E-mini Nasdaq futures...

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index down 0.3% and the

A localized outbreak, even a fatal one, is unlikely to spark the multibillion-dollar revenue catalyst that Moderna needs.

After facing pressure from the summer of 2021 through the end of 2025, Moderna shares have staged an impressive comeback, rallying roughly 50% from their recent lows as investors return their focus to the biotech sector. The rally also received support following reports of a U.S. national testing positive for Hantavirus, as the company disclosed it is exploring an “early-stage and ongoing” treatment program targeting the disease. With those catalysts, let’s examine the technical setup on the daily and monthly charts.

Today, May 11, 2026, AI chip leaders helped steady major U.S. indexes at midday as the Strait of Hormuz remains largely closed.

Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.

The three major US stock indexes were up slightly in late-morning trading Monday after President Don

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) shares continued to extend recent gains on Monday as investors welcomed reports that the company is researching a hantavirus vaccine and advancing early-stage work in the area. Shares of Moderna have added more than 16% in the last five days, trading hands...

Moderna shares are rallying following a report the company is researching a hantavirus vaccine.

Market Catalysts Host Julie Hyman and Yahoo Finance Senior Reporter Brooke DiPalma track several of the day's top trending stock tickers, including memory chip stocks Micron Technology (MU), Intel (INTC), and Qualcomm (QCOM) opening at record highs; shares of Moderna (MRNA) and Novavax (NVAX) reacting to concerns around the hantavirus; and Constellation Energy (CEG) affirming its full-year guidance after beating first quarter earnings estimates.

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 run for the mRNA pioneer. The rally is outpacing fellow vaccine names Pfizer (NYSE:PFE), up 2% near $26.10, and Novavax (NASDAQ:NVAX), basically flat ... Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively tr

Stock Market Today: Futures were down while oil prices rose on Iran tensions. Intel, Lumentum, Moderna, Circle Internet are winners..

Moderna rallies 7% on hopes of hantavirus research.

The company confirmed early-stage hantavirus research as a WHO-confirmed outbreak grows, while flu vaccine data published in a top medical journal

Shares of Moderna (NASDAQ:MRNA) climbed nearly 8% in premarket trading on Monday after reports emerged that a U. S.

President rejects Iran’s response, Warsh’s favored inflation measure, airlines are raising bag fees, and more news to start your day.

Moderna jumps after the U.S. health department says a passenger on a repatriation flight tested mildly positive for hantavirus. Moderna says it’s working on an ‘early-stage and ongoing’ treatment for hantavirus.

Investing.com -- Moderna shares jumped nearly 8% in premarket trading on Monday after a U.S. national tested positive for the Andes strain of hantavirus, drawing attention to the company’s early-stage work on a potential hantavirus treatment.

↗️ Moderna (MRNA): Shares jumped 8% premarket after the biomedical company told media outlets that it has been researching vaccines to protect against hantaviruses since before a recent cruise-ship outbreak.

The U.S. health department said one passenger on a repatriation flight has tested mildly positive for the virus, while another is currently experiencing mild symptoms.

Moderna shares rally as investors bet on recent Hantavirus outbreak accelerating the biotech firm’s path to profitability. But there are ample reasons to avoid buying MRNA stock today.

The stock has rapidly outpaced the broader market, but the long-term implications of the hantavirus are unclear.

Moderna reported positive Phase 3 results for its mRNA seasonal influenza vaccine candidate, mRNA-1010, showing stronger protection than the standard flu shot in a large adult study population. Regulatory submissions for mRNA-1010 are in progress in the US, Europe, Canada, and Australia, with the US FDA reviewing the data and an approval decision expected later this year. Separately, Moderna advanced its mRNA-based hantavirus vaccine collaboration with Korea University's Vaccine Innovation...

CoreWeave drops after missing analysts’ earnings target, while Trade Desk plummets on weak revenue guidance.

Evercore ISI analysts cautioned investors, writing Thursday that “with regards to current headlines, we see no meaningful revenue opportunity.”

Investing.com -- Moderna (NASDAQ:MRNA) shares climbed 10% on Thursday as concerns mounted over a hantavirus outbreak connected to a cruise ship.

Moderna (NASDAQ:MRNA) shareholders approved all four management proposals at the company’s 2026 Annual Meeting of Shareholders, including the re-election of two directors, advisory votes related to executive compensation, and the ratification of Ernst & Young as the company’s independent auditor